In the Pipeline: Encorafenib and Binimetinib in BRAF-Mutated Melanoma

  H&O  What makes the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib a good combination for use in BRAF-mutated melanoma? KF  Like other combinations of […]

The Microbiome: A Basis for Novel Immunomodulation in Mice and Men

  H&O  Why does immunotherapy work better in some patients with melanoma than in others? HZ  We are still unsure about that, but we are working […]

The Best Treatments to Use After Checkpoint Inhibition in Melanoma

H&O  Which patients with melanoma are candidates for checkpoint inhibition? GM  All patients with unresectable metastatic melanoma—stage IV and unresectable stage III disease—are candidates for checkpoint […]

Is There a Role for Single-Agent BRAF Inhibition in Melanoma?

  H&O  What makes BRAF inhibition a good approach to the treatment of melanoma? BC  BRAF inhibitors, especially when combined with MEK inhibitors, are an excellent […]

Is There a Role for Single-Agent MEK Inhibition in Melanoma?

H&O  Which MEK inhibitors have been approved for use in melanoma? DJ  The US Food and Drug Administration has approved 2 MEK inhibitors for use in […]

Update on the Treatment of Uveal Melanoma

  H&O  How common is uveal melanoma, including metastatic uveal melanoma? RC Uveal melanoma is rare, with an incidence of approximately 5 cases per million people […]

What Is Optimal First-Line Treatment of Unresectable or Advanced BRAF-Mutant Melanoma?

H&O  How common are BRAF mutations in patients with melanoma? MA Approximately 50% of patients with melanoma have a V600E or V600K mutation in BRAF, each […]

Tumor and T-Cell Metabolism: New Insights Into Melanoma Therapy

H&O What is the definition of tumor and T-cell metabolism as it applies to cancer? GD The term metabolism is defined as the set of pathways […]

Future Directions for Checkpoint Inhibition in Melanoma

Clinical Advances in Hematology & Oncology February 2016, Volume 14, Issue 2 Omid Hamid, MD Chief of Research/Immuno-Oncology Director of Melanoma Program The Angeles Clinic and […]

Molecular Approaches to Tumor Inhibition in Melanoma

  H&O What molecular agents are currently available for use in melanoma? MD The US Food Administration (FDA) has approved several molecularly targeted agents for use […]

New Drugs in Development for Melanoma

  H&O What are the shortcomings of existing agents for melanoma? KF All of the new melanoma agents approved by the US Food and Drug Administration […]

Advances in Targeted Therapy for Melanoma

Abstract: Metastatic melanoma remains an aggressive malignancy conferring a very poor prognosis, and standard chemotherapeutic and immunologic treatments have not demonstrated an overall survival benefit. No molecularly targeted therapy is approved for the treatment of advanced melanoma. Melanoma is a molecularly heterogeneous malignancy, and optimal treatment in a given patient is likely to depend on the presence of specific molecular abnormalities. Aberrations in components of signal transduction pathways have been identified that modulate melanoma proliferation and survival. Mutations that activate the mitogen activated protein kinase (MAPK) pathway via BRAF or NRAS are present in the majority of melanomas arising on skin intermittently exposed to the sun. Mutations that activate the KIT oncogene are more commonly present in melanomas arising from mucosal, acral, or chronic sun-damaged sites. Inhibitors of the MAPK pathway and of KIT are currently undergoing clinical investigation. In this article, we review advances in targeted strategies to treat different subgroups of patients with melanoma.